Loading...
Loading...
ZYNE| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 8,492.9K |
| Operating I/L | -8,492.9K |
| Other Income/Expense | -183.3K |
| Interest Income | 251.9K |
| Pretax | -8,676.1K |
| Income Tax Expense | 183.3K |
| Net Income/Loss | -8,859.4K |
Zynerba Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company that focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Its main product, Zygel, is a cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company's revenue is generated through the development and potential commercialization of these transdermal cannabinoid therapies, targeting a niche market of rare and near-rare neuropsychiatric disorders.
